TY - JOUR
T1 - Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects
T2 - A cost consequences analysis of data from the FARO study
AU - Roggeri, Daniela Paola
AU - Mazzaferro, Sandro
AU - Brancaccio, Diego
AU - Cannella, Giuseppe
AU - Messa, Piergiorgio
AU - Di Luca, Marina
AU - Morosetti, Massimo
AU - Costanzo, Anna Maria
AU - Paparatti, Umberto Di Luzio
AU - Cornago, Dante
AU - Cozzolino, Mario
PY - 2012/12
Y1 - 2012/12
N2 - Background and objectives: Secondary hyperparathyroidism (SHPT) is a frequent complication of CKD with incidence, prevalence, and costs increasing worldwide. The objective of this analysis was to estimate therapy cost of SHPT in a subpopulation of the FARO study. Materials and methods: In the FARO study, an observational survey aimed to evaluate patterns of treatment in patients with SHPT who had undergone hemodialysis, pharmacological treatments and biochemical parameters evolution data were collected in four surveys. Patients maintaining the same treatment in all sessions were grouped by type of treatment and evaluated for costs from the Italian National Health Service perspective. Results: Four cohorts were identified: patients treated with oral (PO) calcitriol (n=182), intravenous (IV) calcitriol (n=34), IV paricalcitol (n=62), and IV paricalcitol+cinacalcet therapy (n=20); the cinacalcet monotherapy group was not analysed due to low number of patients (n=9). Parathyroid hormone (PTH) level at baseline and effectiveness of treatments in suppressing PTH level were assessed to test comparability among cohorts: calcitriol PO patients were significantly less severe than others (PTH level at baseline lower than 300 pg/ml; p
AB - Background and objectives: Secondary hyperparathyroidism (SHPT) is a frequent complication of CKD with incidence, prevalence, and costs increasing worldwide. The objective of this analysis was to estimate therapy cost of SHPT in a subpopulation of the FARO study. Materials and methods: In the FARO study, an observational survey aimed to evaluate patterns of treatment in patients with SHPT who had undergone hemodialysis, pharmacological treatments and biochemical parameters evolution data were collected in four surveys. Patients maintaining the same treatment in all sessions were grouped by type of treatment and evaluated for costs from the Italian National Health Service perspective. Results: Four cohorts were identified: patients treated with oral (PO) calcitriol (n=182), intravenous (IV) calcitriol (n=34), IV paricalcitol (n=62), and IV paricalcitol+cinacalcet therapy (n=20); the cinacalcet monotherapy group was not analysed due to low number of patients (n=9). Parathyroid hormone (PTH) level at baseline and effectiveness of treatments in suppressing PTH level were assessed to test comparability among cohorts: calcitriol PO patients were significantly less severe than others (PTH level at baseline lower than 300 pg/ml; p
KW - Cost consequences analysis
KW - Haemodialysis
KW - Secondary Hyperparathyroidism
KW - Therapy cost
UR - http://www.scopus.com/inward/record.url?scp=84869860245&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84869860245&partnerID=8YFLogxK
U2 - 10.3111/13696998.2012.703632
DO - 10.3111/13696998.2012.703632
M3 - Article
C2 - 22702445
AN - SCOPUS:84869860245
VL - 15
SP - 1110
EP - 1117
JO - Journal of Medical Economics
JF - Journal of Medical Economics
SN - 1369-6998
IS - 6
ER -